Invitae Corporation (NVTA): Price and Financial Metrics

Invitae Corporation (NVTA): $0.02

0.00 (2.63%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

NVTA Price/Volume Stats

Current price $0.02 52-week high $0.02
Prev. close $0.02 52-week low $0.02
Day low $0.02 Volume 6,533,000
Day high $0.02 Avg. volume 0
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 5.21M

NVTA Stock Price Chart Interactive Chart >

NVTA POWR Grades

  • Growth is the dimension where NVTA ranks best; there it ranks ahead of 84.82% of US stocks.
  • NVTA's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
  • NVTA's current lowest rank is in the Stability metric (where it is better than 11.82% of US stocks).

NVTA Stock Summary

  • NVTA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.2 -- higher than only 2.82% of US-listed equities with positive expected earnings growth.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -4.68 for INVITAE CORP; that's greater than it is for only 3.75% of US stocks.
  • INVITAE CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 82.33%, greater than the shareholder yield of 97.77% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to INVITAE CORP, a group of peers worth examining would be DM, RIOT, COMM, SSRM, and AMWL.
  • Visit NVTA's SEC page to see the company's official filings. To visit the company's web site, go to www.invitae.com.

NVTA Valuation Summary

  • NVTA's price/earnings ratio is -0.1; this is 100.34% lower than that of the median Healthcare stock.
  • NVTA's price/earnings ratio has moved up 20.2 over the prior 108 months.

Below are key valuation metrics over time for NVTA.

Stock Date P/S P/B P/E EV/EBIT
NVTA 2023-12-29 0.4 -0.2 -0.1 -1.1
NVTA 2023-12-28 0.4 -0.2 -0.1 -1.1
NVTA 2023-12-27 0.4 -0.2 -0.1 -1.1
NVTA 2023-12-26 0.4 -0.2 -0.1 -1.1
NVTA 2023-12-22 0.4 -0.2 -0.1 -1.1
NVTA 2023-12-21 0.4 -0.2 -0.1 -1.1

NVTA Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 100.6%.
  • Its 5 year cash and equivalents growth rate is now at 100.6%.
  • The year over year net income to common stockholders growth rate now stands at 26.38%.
Over the past 33 months, NVTA's revenue has gone up $303,146,000.

The table below shows NVTA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 519.97 -586.852 -3,211.6
2022-06-30 500.829 -623.202 -3,108.62
2022-03-31 480.519 -617.838 -451.373
2021-12-31 460.449 -559.815 -379.006
2021-09-30 434.759 -497.479 -408.22
2021-06-30 389.092 -394.593 -312.946

NVTA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVTA has a Quality Grade of D, ranking ahead of 13.88% of graded US stocks.
  • NVTA's asset turnover comes in at 0.118 -- ranking 73rd of 81 Healthcare stocks.
  • BKD, VCYT, and HCSG are the stocks whose asset turnover ratios are most correlated with NVTA.

The table below shows NVTA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.118 0.281 -0.331
2021-03-31 0.139 0.268 -0.887
2020-12-31 0.183 0.291 -1.070
2020-09-30 0.284 0.321 -0.721
2020-06-30 0.280 0.347 -0.790
2020-03-31 0.336 0.429 -0.705

Invitae Corporation (NVTA) Company Bio


Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.


NVTA Latest News Stream


Event/Time News Detail
Loading, please wait...

NVTA Latest Social Stream


Loading social stream, please wait...

View Full NVTA Social Stream

Latest NVTA News From Around the Web

Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Yahoo | December 22, 2023

Invitae Layoffs 2023: What to Know About the Latest NVTA Job Cuts

Invitae layoffs are a hot topic on Friday after the genetics company announced a 15% reduction of its workforce to reduce costs.

William White on InvestorPlace | December 15, 2023

Why Are Chinese Stocks Up Today?

Chinese stocks are up on Friday as investors react to recent economic data that includes signs of recovering in the reigon.

William White on InvestorPlace | December 15, 2023

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts

Invitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn. The company has divested the assets of Ciitizen and announced strategic cost cuts, which will include a workforce reduction and other operating expense reductions.

Yahoo | December 13, 2023

What Makes Invitae (NVTA) a New Buy Stock

Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | December 13, 2023

Read More 'NVTA' Stories Here

NVTA Price Returns

1-mo N/A
3-mo -96.81%
6-mo -96.70%
1-year -98.39%
3-year -99.94%
5-year -99.91%
YTD -96.81%
2023 -66.30%
2022 -87.82%
2021 -63.48%
2020 159.21%
2019 45.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!